Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria
Status:
Completed
Trial end date:
2019-09-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the efficacy and safety of MT-7117 on sunlight
exposure duration without symptoms and tolerance in subjects with EPP.
Phase:
Phase 2
Details
Lead Sponsor:
Mitsubishi Tanabe Pharma Development America, Inc.